178 related articles for article (PubMed ID: 33016133)
1. Safety of the Xuesaitong injection in China: results from a large-scale multicentre post-marketing surveillance study in a real-world setting.
He Y; Gao XM; Li L; Liu XG; Liu W; Hong XJ; Huang BH; Yang HL; Xue MH; Wu XJ; Liu JF
Curr Med Res Opin; 2020 Dec; 36(12):1947-1953. PubMed ID: 33016133
[TBL] [Abstract][Full Text] [Related]
2. Post-marketing safety surveillance and re-evaluation of Xueshuantong injection.
Li C; Xu T; Zhou P; Zhang J; Guan G; Zhang H; Ling X; Li W; Meng F; Liu G; Lv L; Yuan J; Li X; Zhu M
BMC Complement Altern Med; 2018 Oct; 18(1):277. PubMed ID: 30326892
[TBL] [Abstract][Full Text] [Related]
3. Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.
Li J; Li M; Li L; Ma L; Cao A; Wen A; Chen W; Li L; Liang Y; Deng J
BMC Pharmacol Toxicol; 2022 Jul; 23(1):51. PubMed ID: 35842685
[TBL] [Abstract][Full Text] [Related]
4. [Post-marketing surveillance of
Li XX; Zhuo L; Yang YH; Zhan SY; Zhai SD
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Feb; 38(2):248-252. PubMed ID: 28231676
[No Abstract] [Full Text] [Related]
5. [Post-marketing intensive safety monitoring of Injection of Xuesaitong (lyophilized) in 30097 cases].
Xin-Yao J; Ke-Yi W; Jing-Bo Z; Chun-Xiang L; Hui W; Zhi L; Wen-Tai P; Hu-Cheng W; Nan LI; Jun-Hua Z; Wen-Ke Z
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):5029-5033. PubMed ID: 33350279
[TBL] [Abstract][Full Text] [Related]
6. Post-Marketing Safety Surveillance of the Salvia Miltiorrhiza Depside Salt for Infusion: A Real World Study.
Yan YY; Yang YH; Wang WW; Pan YT; Zhan SY; Sun MY; Zhang H; Zhai SD
PLoS One; 2017; 12(1):e0170182. PubMed ID: 28125608
[TBL] [Abstract][Full Text] [Related]
7. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
[TBL] [Abstract][Full Text] [Related]
8. [Post-marketing safety surveillance of Diemailing Kudiezi injection: real world study in 30 233 cases].
Liao X; Yu DD; Xie YM; Zhang YL; He Y; Zhang Y; Liu Y; Yi DH; Wang YY
Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2857-2863. PubMed ID: 29139248
[TBL] [Abstract][Full Text] [Related]
9. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations.
Wang C; Shi QP; Ding F; Jiang XD; Tang W; Yu ML; Cheng JQ
Biomed Pharmacother; 2019 Jan; 109():1523-1531. PubMed ID: 30551404
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of clinical use of post-marketing hospital centralized monitoring of Xiyanping injection].
Zhao Y; Shi C; Huang P
Zhongguo Zhong Yao Za Zhi; 2016 Feb; 41(4):743-747. PubMed ID: 28871704
[TBL] [Abstract][Full Text] [Related]
11. Post-marketing surveillance study with iodixanol in 20 185 Chinese patients from routine clinical practices.
Zhang BC; Hou L; Lv B; Xu YW
Br J Radiol; 2014 Feb; 87(1034):20130325. PubMed ID: 24357597
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China.
Li H; Deng J; Deng L; Ren X; Xia J
Pharmacoepidemiol Drug Saf; 2019 Jul; 28(7):1002-1013. PubMed ID: 31131950
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of Xuesaitong injection combined with western medicines in the treatment of ischemic stroke: an updated systematic review and meta-analysis.
Feng L; Wu XJ; Cao T; Wu B
Ann Palliat Med; 2021 Sep; 10(9):9523-9534. PubMed ID: 34628878
[TBL] [Abstract][Full Text] [Related]
14. ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].
Wu SX; Sun HF; Yang XH; Long HZ; Ye ZG; Ji SL; Zhang L
Zhongguo Zhong Yao Za Zhi; 2014 Aug; 39(15):2983-8. PubMed ID: 25423845
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of model of traditional Chinese medicine injections post-marketing safety monitoring].
Guo XE; Zhao YB; Xie YM; Zhao LC; Li YF; Hao Z
Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2974-8. PubMed ID: 24471314
[TBL] [Abstract][Full Text] [Related]
16. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
[TBL] [Abstract][Full Text] [Related]
17. Safety of traditional Chinese medicine injection based on spontaneous reporting system from 2014 to 2019 in Hubei Province, China.
Huang R; Cai Y; Yang L; Shangguan X; Ghose B; Tang S
Sci Rep; 2021 Apr; 11(1):8875. PubMed ID: 33893351
[TBL] [Abstract][Full Text] [Related]
18. [Study of post marketing safety reevaluation of shenqi fuzheng injection].
Ai QH; Li YY; Xie YM
Zhongguo Zhong Yao Za Zhi; 2014 Sep; 39(18):3633-6. PubMed ID: 25532410
[TBL] [Abstract][Full Text] [Related]
19. HLA-C*12:02 is strongly associated with Xuesaitong-induced cutaneous adverse drug reactions.
Yan S; Xiong H; Shao F; Zhang W; Yang F; Qi Z; Chen S; He L; Jiang M; Su Y; Zhu H; Qin S; Zhu Q; Luo X; Xing Q
Pharmacogenomics J; 2019 Jun; 19(3):277-285. PubMed ID: 30237582
[TBL] [Abstract][Full Text] [Related]
20. [Retrospective analysis and discussion on 74 cases of adverse reactions of traditional Chinese medicine injection].
Wang Y; Fan LP; Song J; Cai YP; Jinang TT; Wang YG; Kong XW; Wu JR
Zhongguo Zhong Yao Za Zhi; 2018 Nov; 43(21):4347-4351. PubMed ID: 30583639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
